DEC-205 is an endocytic receptor expressed by a distinct CD8 alpha+ dendritic cell subpopulation. Targeting of proteins to DEC-205 through chimeric antibody constructs causes clonal deletion or anergy of antigen-specific CD4+ and CD8+ T cells in immunologically normal mice. In NOD mice, a mouse model for autoimmune diabetes, beta cell-specific CD8+ T cells can be depleted by anti-DEC antigen treatment (Mukhopadhaya A, et al. PNAS 2008). Using DEC-205 targeting, we have now determined that in autoimmune NOD mice, CD8 DCs are not able to induce CD4+ T cell tolerance. NOD mice were injected with BDC2.5 T cell receptor (TCR) transgenic CD4+ T cells that recognize the beta cell antigen chromogranin A, followed by treatment with anti-DEC-205 attached to a BDC mimeotope peptide. Three days after anti-DEC-205 treatment, BDC T cells had proliferated in lymphoid organs, similar to results in normal mice. However, ten days after treatment with anti-DEC-205, when T cells are deleted in normal mice, antigen-specific cells remained in the autoimmune mice and were not anergic (they retained capacity to produce interferon gamma). In addition, no increase in regulatory T cells was observed. Therefore, antigen targeted to NOD CD8 DCs does not induce deletion, anergy or regulatory T cells (the 3 main mechanisms of peripheral T cell tolerance). We are interested in what immune pathways may be important for restoring tolerance in this setting. CD40/CD40L interactions are one pathway that may be important: when a blocking antibody specific for anti-CD40L was given with anti-DEC-205 antigen, T cell responses were more tolerogenic. CD11b+ dendritic cells express DCIR2 on their surface, and antibodies specific for DCIR2 can be used to target antigens to this DC subset. We are now measuring BDC2.5 TCR transgenic T cell responses after stimulation in vivo with anti-DCIR2-targeted BDC peptide in NOD mice. We are also testing whether this antibody-antigen combination can alter diabetes development.

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2012
Total Cost
$557,574
Indirect Cost
City
State
Country
Zip Code
Hotta-Iwamura, Chie; Tarbell, Kristin V (2016) Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol 100:65-80
Price, Jeffrey D; Tarbell, Kristin V (2015) The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol 6:288
Price, Jeffrey D; Hotta-Iwamura, Chie; Zhao, Yongge et al. (2015) DCIR2+ cDC2 DCs and Zbtb32 restore CD4+ T cell tolerance and inhibit diabetes. Diabetes :
Price, Jeffrey D; Beauchamp, Nicole M; Rahir, Gwendoline et al. (2014) CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol 95:325-36
Mukherjee, Gayatri; Geliebter, Ari; Babad, Jeffrey et al. (2013) DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1. Int Immunol 25:651-60
Gardner, James M; Metzger, Todd C; McMahon, Eileen J et al. (2013) Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4⁺ T cells. Immunity 39:560-72